Elicera Therapeutics AB (OSTO:ELIC) Net Change in Cash : kr-1.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Elicera Therapeutics AB's Net Change in Cash for the three months ended in Mar. 2024 was kr11.32 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.08 Mil.

Elicera Therapeutics AB Net Change in Cash Historical Data

The historical data trend for Elicera Therapeutics AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Net Change in Cash Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

-0.02

11.53

40.83

-8.57

-14.44

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial													-2.04	-1.66	-14.24	3.50	11.32

Elicera Therapeutics AB Net Change in Cash Calculation

Elicera Therapeutics AB's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-14.923	+	0.483	+	0	+	0
	=	-14.44

Elicera Therapeutics AB's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -9.264 + 0 + 20.587 + 0

= 11.32

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Elicera Therapeutics AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Net Change in Cash

Comparable Companies

OSTO:ISOFOL OSTO:SPRINT OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL XSAT:CESSA OSTO:ACE OSTO:ZICC OSTO:SIMRIS B OSTO:LIPUM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines